

# Christos Sachpekidis

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1791951/publications.pdf>

Version: 2024-02-01

78  
papers

1,961  
citations

257450

24  
h-index

276875

41  
g-index

80  
all docs

80  
docs citations

80  
times ranked

2332  
citing authors

#	ARTICLE	IF	CITATIONS
1	Parametric Imaging With Dynamic PET for Oncological Applications: Protocols, Interpretation, Current Applications and Limitations for Clinical Use. <i>Seminars in Nuclear Medicine</i> , 2022, 52, 312-329.	4.6	10
2	Editorial: Molecular Imaging in Multiple Myeloma: An Update and Future Perspectives. <i>Frontiers in Nuclear Medicine</i> , 2022, 2, .	1.2	0
3	Equilibrium radionuclide angiography: Intra- and inter-observer repeatability and reproducibility in the assessment of cardiac systolic and diastolic function. <i>Journal of Nuclear Cardiology</i> , 2021, 28, 1304-1314.	2.1	7
4	Multimodal Imaging With Positron Emission Tomography/Computed Tomography and Magnetic Resonance Imaging to Detect Extracapsular Extension in Head and Neck Cancer. <i>Laryngoscope</i> , 2021, 131, E163-E169.	2.0	4
5	Combination of Forced Diuresis with Additional Late Imaging in <sup>68</sup> Ga-PSMA-11 PET/CT: Effects on Lesion Visibility and Radiotracer Uptake. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1252-1257.	5.0	26
6	Digital PET/CT allows for shorter acquisition protocols or reduced radiopharmaceutical dose in [18F]-FDG PET/CT. <i>Annals of Nuclear Medicine</i> , 2021, 35, 485-492.	2.2	34
7	Quantitative Dynamic 18F-FDG PET/CT in Survival Prediction of Metastatic Melanoma under PD-1 Inhibitors. <i>Cancers</i> , 2021, 13, 1019.	3.7	12
8	PET Diagnostic Molecules Utilizing Multimeric Cyclic RGD Peptide Analogs for Imaging Integrin $\alpha_5\beta_3$ Receptors. <i>Molecules</i> , 2021, 26, 1792.	3.8	25
9	Quantitative, Dynamic 18F-FDG PET/CT in Monitoring of Smoldering Myeloma: A Case Report. <i>Diagnostics</i> , 2021, 11, 649.	2.6	2
10	The influence of digital PET/CT on diagnostic certainty and interrater reliability in [68Ga]Ga-PSMA-11 PET/CT for recurrent prostate cancer. <i>European Radiology</i> , 2021, 31, 8030-8039.	4.5	19
11	Complete Metabolic Response in FDG-PET-CT Scan before Discontinuation of Immune Checkpoint Inhibitors Correlates with Long Progression-Free Survival. <i>Cancers</i> , 2021, 13, 2616.	3.7	8
12	Assessment of early metabolic progression in melanoma patients under immunotherapy: an 18F-FDG PET/CT study. <i>EJNMMI Research</i> , 2021, 11, 89.	2.5	15
13	Kinetic modeling and parametric imaging with dynamic PET for oncological applications: general considerations, current clinical applications, and future perspectives. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 21-39.	6.4	96
14	Interim [18F]FDG PET/CT can predict response to anti-PD-1 treatment in metastatic melanoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 1932-1943.	6.4	17
15	Fractal and Multifractal Analysis of PET-CT Images for Therapy Assessment of Metastatic Melanoma Patients under PD-1 Inhibitors: A Feasibility Study. <i>Cancers</i> , 2021, 13, 5170.	3.7	1
16	The prognostic significance of [18F]FDG PET/CT in multiple myeloma according to novel interpretation criteria (IMPeTUs). <i>EJNMMI Research</i> , 2021, 11, 100.	2.5	12
17	Dynamic patterns of [68Ga]Ga-PSMA-11 uptake in recurrent prostate cancer lesions. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 160-167.	6.4	25
18	68Ga-PSMA-11 PET/CT in patients with recurrent prostate cancer—a modified protocol compared with the common protocol. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 624-631.	6.4	26

#	ARTICLE	IF	CITATIONS
19	Positron Emission Tomography (PET) Radiopharmaceuticals in Multiple Myeloma. <i>Molecules</i> , 2020, 25, 134.	3.8	18
20	STAT3 Relays a Differential Response to Melanoma-Associated NRAS Mutations. <i>Cancers</i> , 2020, 12, 119.	3.7	9
21	The role of additional late PSMA-ligand PET/CT in the differentiation between lymph node metastases and ganglia. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 642-651.	6.4	29
22	18F-PSMA-1007 multiparametric, dynamic PET/CT in biochemical relapse and progression of prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 592-602.	6.4	26
23	Digital versus analogue PET in [68Ga]Ga-PSMA-11 PET/CT for recurrent prostate cancer: a matched-pair comparison. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 614-623.	6.4	47
24	99mTc-MAG3 Diuretic Renography: Intra- and Inter-Observer Repeatability in the Assessment of Renal Function. <i>Diagnostics</i> , 2020, 10, 709.	2.6	5
25	Positron Emission Tomography in Merkel Cell Carcinoma. <i>Cancers</i> , 2020, 12, 2897.	3.7	9
26	Can 18F-NaF PET/CT before Autologous Stem Cell Transplantation Predict Survival in Multiple Myeloma?. <i>Cancers</i> , 2020, 12, 1335.	3.7	6
27	Radiosynoviorthesis after Surgery in the Treatment of Patients with Ankle Pigmented Villonodular Synovitis: A Case Series. <i>Journal of Clinical Medicine</i> , 2020, 9, 597.	2.4	5
28	PSMA-negative prostate cancer and the continued value of choline-PET/CT. <i>Nuklearmedizin - NuclearMedicine</i> , 2020, 59, 33-34.	0.7	15
29	Imaging and Imaging-Based Management of Pediatric Thyroid Nodules. <i>Journal of Clinical Medicine</i> , 2020, 9, 384.	2.4	17
30	Public Adverse Event Data Insights into the Safety of Pembrolizumab in Melanoma Patients. <i>Cancers</i> , 2020, 12, 1008.	3.7	3
31	Incidental SARS-CoV-2-related findings in asymptomatic patients in [18F]-FDG-PET/CT—potential insights. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2068-2069.	6.4	11
32	Melanoma: 18F-FDG PET/CT for Response Assessment of Melanoma Following Immunotherapy. , 2020, , 55-65.		3
33	Radiosynovectomy is a safe and an efficient alternative in the treatment of chronic, recurrent knee hemarthrosis. <i>World Journal of Nuclear Medicine</i> , 2020, 19, 165.	0.5	0
34	Atypical metastatic pattern of prostate cancer detected with 68Ga-PSMA PET/CT. <i>Nuklearmedizin - NuclearMedicine</i> , 2020, 59, 85-86.	0.7	0
35	F-FDG PET/CT in treatment response evaluation of Burkitt lymphoma: complete remission of a peritoneal super scan. <i>Hellenic Journal of Nuclear Medicine</i> , 2020, 23, 76-78.	0.3	0
36	Clinical significance of signs of autoimmune colitis in <sup>18</sup> F-fluorodeoxyglucose positron emission tomography-computed tomography of 100 stage-IV melanoma patients. <i>Immunotherapy</i> , 2019, 11, 667-676.	2.0	41

#	ARTICLE	IF	CITATIONS
37	Comparison of PSMA-ligand PET/CT and multiparametric MRI for the detection of recurrent prostate cancer in the pelvis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 2289-2297.	6.4	19
38	PSMA radioligand therapy in prostate cancer: overview, latest advances and remaining challenges. <i>Immunotherapy</i> , 2019, 11, 1267-1271.	2.0	3
39	Radioimmunotherapy in Non-Hodgkin's Lymphoma: Retrospective Adverse Event Profiling of Zevalin and Bexxar. <i>Pharmaceuticals</i> , 2019, 12, 141.	3.8	29
40	Neoadjuvant Pazopanib Treatment in High-Risk Soft Tissue Sarcoma: A Quantitative Dynamic 18F-FDG PET/CT Study of the German Interdisciplinary Sarcoma Group. <i>Cancers</i> , 2019, 11, 790.	3.7	11
41	Retrospective Toxicological Profiling of Radium-223 Dichloride for the Treatment of Bone Metastases in Prostate Cancer Using Adverse Event Data. <i>Medicina (Lithuania)</i> , 2019, 55, 149.	2.0	17
42	Bispecific radioligands targeting prostate-specific membrane antigen and gastrin-releasing peptide receptors on the surface of prostate cancer cells. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2019, 62, 510-522.	1.0	7
43	Preoperative Pazopanib in High-Risk Soft Tissue Sarcoma: Phase II Window-of Opportunity Study of the German Interdisciplinary Sarcoma Group (NOPASS/GISG-04). <i>Annals of Surgical Oncology</i> , 2019, 26, 1332-1339.	1.5	12
44	Quantitative dynamic <sup>18</sup> F-fluorodeoxyglucose positron emission tomography/computed tomography before autologous stem cell transplantation predicts survival in multiple myeloma. <i>Haematologica</i> , 2019, 104, e420-e423.	3.5	12
45	Radiogenomic Analysis of F-18-Fluorodeoxyglucose Positron Emission Tomography and Gene Expression Data Elucidates the Epidemiological Complexity of Colorectal Cancer Landscape. <i>Computational and Structural Biotechnology Journal</i> , 2019, 17, 177-185.	4.1	51
46	18F-FDG PET/CT longitudinal studies in patients with advanced metastatic melanoma for response evaluation of combination treatment with vemurafenib and ipilimumab. <i>Melanoma Research</i> , 2019, 29, 178-186.	1.2	43
47	<sup>68</sup> Ga-Prostate-Specific Membrane Antigen Uptake in a Malignant Pleural Effusion From Metastatic Prostate Cancer After Pleurodesis. <i>Clinical Nuclear Medicine</i> , 2019, 44, 838-839.	1.3	1
48	Can benign lymphoid tissue changes in 18F-FDG PET/CT predict response to immunotherapy in metastatic melanoma?. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 297-303.	4.2	45
49	The role of interim 18F-FDG PET/CT in prediction of response to ipilimumab treatment in metastatic melanoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1289-1296.	6.4	90
50	Assessment of glucose metabolism and cellular proliferation in multiple myeloma: a first report on combined 18F-FDG and 18F-FLT PET/CT imaging. <i>EJNMMI Research</i> , 2018, 8, 28.	2.5	17
51	<sup>68</sup> Ga-PSMA PET/CT in the evaluation of bone metastases in prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 904-912.	6.4	34
52	Absolute number of new lesions on 18F-FDG PET/CT is more predictive of clinical response than SUV changes in metastatic melanoma patients receiving ipilimumab. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 376-383.	6.4	160
53	Targeted Therapy-Resistant Melanoma Cells Acquire Transcriptomic Similarities with Human Melanoblasts. <i>Cancers</i> , 2018, 10, 451.	3.7	12
54	Impact of FDG-PET on the Detection of Patients with Lung Cancer at High Risk for ILD. <i>In Vivo</i> , 2018, 32, 1457-1462.	1.3	2

#	ARTICLE	IF	CITATIONS
55	Retrospective Side Effect Profiling of the Metastatic Melanoma Combination Therapy Ipilimumab-Nivolumab Using Adverse Event Data. <i>Diagnostics</i> , 2018, 8, 76.	2.6	23
56	Longitudinal studies of the 18F-FDG kinetics after ipilimumab treatment in metastatic melanoma patients based on dynamic FDG PET/CT. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 1261-1270.	4.2	22
57	Prospective Evaluation of 18-F FDG PET/CT and Biopsies of Osteolytic Lesions and Random Bone Marrow Samples in Newly Diagnosed Multiple Myeloma Patients. <i>Blood</i> , 2018, 132, 3180-3180.	1.4	1
58	Ga-PSMA-11 PET/CT in prostate cancer local recurrence: impact of early images and parametric analysis. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 8, 351-359.	1.0	9
59	Imaging therapy response of gastrointestinal stromal tumors (GIST) with FDG PET, CT and MRI: a systematic review. <i>Clinical and Translational Imaging</i> , 2017, 5, 183-197.	2.1	59
60	18F-FDG PET/CT of Papillary Carcinoma in a Lateral Thyroglossal Duct Cyst. <i>Clinical Nuclear Medicine</i> , 2017, 42, e371-e374.	1.3	10
61	Local recurrence of prostate cancer after radical prostatectomy is at risk to be missed in 68Ga-PSMA-11-PET of PET/CT and PET/MRI: comparison with mpMRI integrated in simultaneous PET/MRI. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 776-787.	6.4	124
62	Treatment response evaluation with 18F-FDG PET/CT and 18F-NaF PET/CT in multiple myeloma patients undergoing high-dose chemotherapy and autologous stem cell transplantation. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 50-62.	6.4	37
63	Functional Imaging with 18F-FDG PET/CT and Diffusion Weighted Imaging (DWI) in Early Response Evaluation of Combination Therapy of Elotuzumab, Lenalidomide, and Dexamethasone in a Relapsed Multiple Myeloma Patient. <i>Diagnostics</i> , 2017, 7, 61.	2.6	1
64	Metastatic melanoma response to combination therapy with ipilimumab and vemurafenib. <i>Hellenic Journal of Nuclear Medicine</i> , 2017, 20, 251-253.	0.3	1
65	Quantitative analysis of F-NaF dynamic PET/CT cannot differentiate malignant from benign lesions in multiple myeloma. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 7, 148-156.	1.0	7
66	18F-FDG PET/CT Reveals Disease Remission in a Patient With Ipilimumab-Refractory Advanced Melanoma Treated With Pembrolizumab. <i>Clinical Nuclear Medicine</i> , 2016, 41, 156-158.	1.3	5
67	68Ga-PSMA-11 Dynamic PET/CT Imaging in Primary Prostate Cancer. <i>Clinical Nuclear Medicine</i> , 2016, 41, e473-e479.	1.3	86
68	Fractal and multifractal analysis of PET/CT images of metastatic melanoma before and after treatment with ipilimumab. <i>EJNMMI Research</i> , 2016, 6, 61.	2.5	29
69	Detection of a primary tumor in the area of the renal artery with 18F-FDG PET/CT in a patient with metastatic undifferentiated sarcoma and a history of mid-aortic syndrome. <i>Medicine (United States)</i> , 2016, 95, e4622.	1.0	3
70	18F-FDG Dynamic PET/CT in Patients with Multiple Myeloma. <i>Clinical Nuclear Medicine</i> , 2015, 40, e300-e307.	1.3	41
71	Predictive value of early 18F-FDG PET/CT studies for treatment response evaluation to ipilimumab in metastatic melanoma: preliminary results of an ongoing study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 386-396.	6.4	130
72	NF1 loss induces senescence during human melanocyte differentiation in an iPSC-based model. <i>Pigment Cell and Melanoma Research</i> , 2015, 28, 407-416.	3.3	52

#	ARTICLE	IF	CITATIONS
73	Combined use of (18)F-FDG and (18)F-FMISO in unresectable non-small cell lung cancer patients planned for radiotherapy: a dynamic PET/CT study. American Journal of Nuclear Medicine and Molecular Imaging, 2015, 5, 127-42.	1.0	24
74	Comparison of (18)F-FDG PET/CT and PET/MRI in patients with multiple myeloma. American Journal of Nuclear Medicine and Molecular Imaging, 2015, 5, 469-78.	1.0	44
75	Application of (18)F-FDG PET and diffusion weighted imaging (DWI) in multiple myeloma: comparison of functional imaging modalities. American Journal of Nuclear Medicine and Molecular Imaging, 2015, 5, 479-92.	1.0	45
76	PET/CT studies of multiple myeloma using 18â€‰F-FDG and 18â€‰F-NaF: comparison of distribution patterns and tracersâ€™ pharmacokinetics. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 1343-1353.	6.4	55
77	Dynamic 18F-fluorodeoxyglucose positron emission tomography/CT in hibernoma: Enhanced tracer uptake mimicking liposarcoma. World Journal of Radiology, 2013, 5, 498.	1.1	5
78	Emotional impairment in a patient with amyotrophic lateral sclerosis: a (99m)Tc-HMPAO SPET brain study. Hellenic Journal of Nuclear Medicine, 2012, 15, 59-62.	0.3	0